Title: Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
Journal: Viruses 20151201
Title: Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901
Title: Hepatitis C virus: Virology, diagnosis and treatment.
Journal: World journal of hepatology 20150608
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: Changing the face of hepatitis C management - the design and development of sofosbuvir.
Journal: Drug design, development and therapy 20150101
Title: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Journal: BMC gastroenterology 20150101
Title: Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
Journal: Journal of medicinal chemistry 20140313
Title: Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Journal: Hepatology (Baltimore, Md.) 20140201
Title: New treatments for genotype 1 chronic hepatitis C - focus on simeprevir.
Journal: Therapeutics and clinical risk management 20140101
Title: Simeprevir for the treatment of hepatitis C virus infection.
Journal: Pharmacogenomics and personalized medicine 20140101
Title: Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
Journal: Bioorganic & medicinal chemistry letters 20121215
Title: Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
Journal: Journal of hepatology 20120601
Title: Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
Journal: Journal of medicinal chemistry 20120412
Title: Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
Journal: Antiviral research 20120101
Title: Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
Journal: Gastroenterology 20110901
Title: Second-wave protease inhibitors: choosing an heir.
Journal: Clinics in liver disease 20110801
Title: Therapeutics: new drugs hit the target.
Journal: Nature 20110608
Title: Emerging therapeutic options in hepatitis C virus infection.
Journal: The American journal of managed care 20110301
Title: Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Journal: Antiviral therapy 20110101
Title: Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Journal: Bioorganic & medicinal chemistry letters 20101215
Title: Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
Journal: Antimicrobial agents and chemotherapy 20101201
Title: Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
Journal: Bioorganic & medicinal chemistry 20100715
Title: In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Journal: Antimicrobial agents and chemotherapy 20100501
Title: Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Journal: Gastroenterology 20100301
Title: Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.
Journal: Angewandte Chemie (International ed. in English) 20100222
Title: Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.
Journal: Current topics in medicinal chemistry 20100101
Title: [New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].
Journal: Lakartidningen 20091101
Title: TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Journal: Current opinion in investigational drugs (London, England : 2000) 20090801
Title: In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
Journal: Antimicrobial agents and chemotherapy 20090401
Title: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
Journal: Bioorganic & medicinal chemistry letters 20080901
Title: Raboisson P, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4853-8.
Title: Lin TI, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.Antimicrob Agents Chemother. 2009 Apr;53(4):1377-85. Epub 2009 Jan 26.
Title: Rajagopalan R, et al. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease. Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01569-16.
Title: Lo HS, et al. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. ACS Cent Sci. 2021 May 26;7(5):792-802.
